March Biosciences (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- October 23, 2024
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $28,400,000
Company Info
- Traction
- March Bio has raised over $51 million to date inclusive of all dilutive and non-dilutive funding.
- Founders
- Sarah Hein
- Company Description
- March Biosciences is an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia, with promising signals of efficacy and safety to date.
- Market
- Cancer treatment
- Location
- Houston, Texas, United States
- Coinvestors
- Mission BioCapital, 4BIO Capital, KdT Ventures, Alexandria Venture Investments, Volnay Therapeutics, Modi Ventures, Mansueto Investments, TMC Venture Fund, Cancer Focus Fund, Small Ventures, Portal Innovations